PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAtovaquone
Atovaquone
Atovaquone, Malarone, Mepron (atovaquone) is a small molecule pharmaceutical. Atovaquone was first approved as Mepron on 1992-11-25. It is used to treat cerebral toxoplasmosis, malaria, and pneumocystis pneumonia in the USA. It is known to target Cytochrome b.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
nervous system diseasesD009422
Trade Name
FDA
EMA
Atovaquone, Mepron (discontinued: Mepron)
Combinations
Atovaquone proguanil, Malarone
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atovaquone
+
Proguanil hydrochloride
Tradename
Company
Number
Date
Products
MALARONEGSKN-021078 RX2000-07-14
1 products, RLD, RS
MALARONE PEDIATRICGSKN-021078 RX2000-07-14
1 products, RLD
Atovaquone
Tradename
Company
Number
Date
Products
MEPRONGSKN-020500 RX1995-02-08
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
atovaquoneANDA2025-03-20
atovaquone and proguanil hclNDA authorized generic2023-10-23
atovaquone and proguanil hydrochlorideANDA2024-10-10
atovaquone and proguanil hydrochloride atovaquone and proguanil hydrochloride pediatricANDA2019-12-31
atovaquone oral suspensionANDA2024-02-15
malaroneNew Drug Application2023-11-14
mepronNew Drug Application2023-07-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
malariaEFO_0001068D008288B54
cerebral toxoplasmosisEFO_0007200D016781B58.2
pneumocystis pneumoniaEFO_0007448D011020B59
falciparum malariaEFO_0007444D016778B50
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AX: Other agents against amoebiasis and other protozoal diseases in atc
— P01AX06: Atovaquone
— P01B: Antimalarials
— P01BB: Biguanide antimalarials
— P01BB51: Proguanil and atovaquone
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B541————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAtovaquone
INNatovaquone
Description
Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. It has a role as an antimalarial, an antifungal agent, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor and an EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor. It is a member of monochlorobenzenes and a hydroxy-1,4-naphthoquinone.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Identifiers
PDB—
CAS-ID95233-18-4
RxCUI—
ChEMBL IDCHEMBL1450
ChEBI ID575568
PubChem CID74989
DrugBankDB01117
UNII IDY883P1Z2LT (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
MT-CYB
MT-CYB
Organism
Plasmodium falciparum
Gene name
MT-CYB
Gene synonyms
COB, CYTB, MTCYB
NCBI Gene ID
—
Protein name
Cytochrome b
Protein synonyms
Complex III subunit 3, Complex III subunit III, Cytochrome b-c1 complex subunit 3, Ubiquinol-cytochrome-c reductase complex cytochrome b subunit
Uniprot ID
Q02768
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Atovaquone – Amneal Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Atovaquone
+
Proguanil
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 6,347 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,648 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use